AU2017378419A1 - Treating degenerative dementia using low intensity focused ultrasound pulsation (lifup) device - Google Patents
Treating degenerative dementia using low intensity focused ultrasound pulsation (lifup) device Download PDFInfo
- Publication number
- AU2017378419A1 AU2017378419A1 AU2017378419A AU2017378419A AU2017378419A1 AU 2017378419 A1 AU2017378419 A1 AU 2017378419A1 AU 2017378419 A AU2017378419 A AU 2017378419A AU 2017378419 A AU2017378419 A AU 2017378419A AU 2017378419 A1 AU2017378419 A1 AU 2017378419A1
- Authority
- AU
- Australia
- Prior art keywords
- brain
- transducer
- ultrasonic
- target area
- ultrasonic beam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 46
- 230000003412 degenerative effect Effects 0.000 title claims abstract description 32
- 238000002604 ultrasonography Methods 0.000 title description 30
- 230000010349 pulsation Effects 0.000 title description 4
- 210000004556 brain Anatomy 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000007958 sleep Effects 0.000 claims abstract description 30
- 210000001130 astrocyte Anatomy 0.000 claims abstract description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 18
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 13
- 230000004913 activation Effects 0.000 claims abstract description 10
- 210000002569 neuron Anatomy 0.000 claims abstract description 7
- 230000037361 pathway Effects 0.000 claims abstract description 6
- 210000005013 brain tissue Anatomy 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 3
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims description 5
- 229960004253 dexmedetomidine Drugs 0.000 claims description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 230000003710 glymphatic flow Effects 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 claims description 2
- 230000030214 innervation Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 13
- 230000003925 brain function Effects 0.000 abstract description 3
- 210000003128 head Anatomy 0.000 description 76
- 238000002595 magnetic resonance imaging Methods 0.000 description 30
- 239000012528 membrane Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 22
- 230000002123 temporal effect Effects 0.000 description 16
- 210000003625 skull Anatomy 0.000 description 15
- 230000003028 elevating effect Effects 0.000 description 13
- 230000015654 memory Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 9
- 230000037322 slow-wave sleep Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000000712 assembly Effects 0.000 description 8
- 238000000429 assembly Methods 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 210000003478 temporal lobe Anatomy 0.000 description 8
- 238000009210 therapy by ultrasound Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000005540 biological transmission Effects 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000627 locus coeruleus Anatomy 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 230000001936 parietal effect Effects 0.000 description 4
- 230000002360 prefrontal effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000974 brodmann area Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000001353 entorhinal cortex Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000003388 posterior cerebral artery Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000005196 temporal scalp Anatomy 0.000 description 2
- 238000001931 thermography Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030312 On and off phenomenon Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 1
- 229960004823 armodafinil Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000037185 brain physiology Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003715 interstitial flow Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0021—Neural system treatment
- A61N2007/0026—Stimulation of nerve tissue
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434744P | 2016-12-15 | 2016-12-15 | |
| US62/434,744 | 2016-12-15 | ||
| PCT/US2017/066532 WO2018112269A1 (en) | 2016-12-15 | 2017-12-14 | Treating degenerative dementia using low intensity focused ultrasound pulsation (lifup) device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017378419A1 true AU2017378419A1 (en) | 2019-07-04 |
Family
ID=62559240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017378419A Abandoned AU2017378419A1 (en) | 2016-12-15 | 2017-12-14 | Treating degenerative dementia using low intensity focused ultrasound pulsation (lifup) device |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3554636B1 (https=) |
| JP (2) | JP7237835B2 (https=) |
| AU (1) | AU2017378419A1 (https=) |
| CA (1) | CA3046335A1 (https=) |
| ES (1) | ES2896128T3 (https=) |
| IL (1) | IL267307A (https=) |
| WO (1) | WO2018112269A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10974078B2 (en) | 2012-12-27 | 2021-04-13 | Brainsonix Corporation | Treating degenerative dementia with low intensity focused ultrasound pulsation (LIFUP) device |
| US9061133B2 (en) | 2012-12-27 | 2015-06-23 | Brainsonix Corporation | Focused ultrasonic transducer navigation system |
| US10512794B2 (en) | 2016-12-16 | 2019-12-24 | Brainsonix Corporation | Stereotactic frame |
| WO2020210813A1 (en) * | 2019-04-11 | 2020-10-15 | The General Hospital Corporation | Generating imaging-based neurological state biomarkers and estimating cerebrospinal fluid (csf) dynamics based on coupled neural and csf oscillations during sleep |
| CN110507917A (zh) * | 2019-07-30 | 2019-11-29 | 哈尔滨医科大学 | 一种超高场磁共振引导的低强度聚焦超声爆破系统 |
| CN110975176B (zh) * | 2019-12-27 | 2021-04-27 | 中国人民解放军总医院 | 一种用于人体脑部磁波刀的自动调控的方法和装置 |
| US11759661B2 (en) | 2020-05-20 | 2023-09-19 | Brainsonix Corporation | Ultrasonic transducer treatment device |
| US12257446B2 (en) | 2020-08-24 | 2025-03-25 | Brainsonix Corporation | Systems and methods for neuromodulation of neuronal circuits using transcranial focused microwave pulses |
| KR102637479B1 (ko) * | 2020-11-18 | 2024-02-16 | 주식회사 뉴로소나 | 저강도 집속 초음파 치료 장치 |
| EP4342394A1 (de) | 2022-09-23 | 2024-03-27 | MTS Medical UG | Vorrichtung und system zur behandlung von alzheimererkrankungen |
| WO2025013486A1 (ja) * | 2023-07-07 | 2025-01-16 | サウンドウェーブイノベーション株式会社 | 超音波治療装置 |
| JP2025020754A (ja) * | 2023-07-31 | 2025-02-13 | 株式会社リコー | 生体内液流促進装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015903A1 (de) * | 1997-09-19 | 1999-04-01 | Evotec Biosystems Ag | Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen |
| US20050020945A1 (en) * | 2002-07-02 | 2005-01-27 | Tosaya Carol A. | Acoustically-aided cerebrospinal-fluid manipulation for neurodegenerative disease therapy |
| US20120197163A1 (en) * | 2011-01-27 | 2012-08-02 | Mishelevich David J | Patterned control of ultrasound for neuromodulation |
| US20110270138A1 (en) * | 2010-05-02 | 2011-11-03 | Mishelevich David J | Ultrasound macro-pulse and micro-pulse shapes for neuromodulation |
| US20120296241A1 (en) * | 2011-05-22 | 2012-11-22 | Mishelevich David J | Ultrasound neuromodulation for treatment of autism spectrum disorder and alzheimers disease and other dementias |
| US20140186423A1 (en) * | 2012-03-27 | 2014-07-03 | Mathew Gelfand | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease |
| US20140058293A1 (en) * | 2012-05-23 | 2014-02-27 | Sunnybrook Research Institute | Multi-Frequency Ultrasound Device and Method of Operation |
| US9061133B2 (en) | 2012-12-27 | 2015-06-23 | Brainsonix Corporation | Focused ultrasonic transducer navigation system |
| WO2015192189A1 (en) * | 2014-06-20 | 2015-12-23 | The University Of Queensland | Neurodegenerative disease treatment |
| TWI615172B (zh) * | 2014-09-04 | 2018-02-21 | 國立陽明大學 | 低強度脈衝式超音波裝置用於治療及／或預防神經退化性疾病的用途 |
| JP6585836B2 (ja) | 2016-05-12 | 2019-10-02 | 株式会社日立製作所 | エネルギー照射装置 |
-
2017
- 2017-12-14 CA CA3046335A patent/CA3046335A1/en active Pending
- 2017-12-14 ES ES17880009T patent/ES2896128T3/es active Active
- 2017-12-14 JP JP2019532946A patent/JP7237835B2/ja active Active
- 2017-12-14 EP EP17880009.0A patent/EP3554636B1/en active Active
- 2017-12-14 WO PCT/US2017/066532 patent/WO2018112269A1/en not_active Ceased
- 2017-12-14 AU AU2017378419A patent/AU2017378419A1/en not_active Abandoned
-
2019
- 2019-06-13 IL IL267307A patent/IL267307A/en unknown
-
2022
- 2022-02-10 JP JP2022019312A patent/JP2022062218A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018112269A1 (en) | 2018-06-21 |
| JP2020501734A (ja) | 2020-01-23 |
| EP3554636A4 (en) | 2020-08-19 |
| EP3554636A1 (en) | 2019-10-23 |
| IL267307A (en) | 2019-08-29 |
| EP3554636B1 (en) | 2021-09-01 |
| JP7237835B2 (ja) | 2023-03-13 |
| ES2896128T3 (es) | 2022-02-24 |
| JP2022062218A (ja) | 2022-04-19 |
| CA3046335A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12350524B2 (en) | Treating degenerative dementia with low intensity focused ultrasound pulsation (LIFUP) device | |
| EP3554636B1 (en) | Treating degenerative dementia using low intensity focused ultrasound pulsation (lifup) device | |
| Lee et al. | Pilot study of focused ultrasound for drug‐resistant epilepsy | |
| JP7138215B2 (ja) | 検出装置及び関連する撮像方法 | |
| US9630029B2 (en) | Focused ultrasonic transducer navigation system | |
| CA2789096C (en) | Apparatus for the treatment of brain affections and method implementing thereof | |
| US20180028841A1 (en) | Methods and systems for peripheral nerve modulation using focused ultrasound | |
| US20140194726A1 (en) | Ultrasound Neuromodulation for Cognitive Enhancement | |
| US20130338424A1 (en) | Transcranial magnetic stimulation (tms) methods and apparatus | |
| US20150151142A1 (en) | Device and Methods for Targeting of Transcranial Ultrasound Neuromodulation by Automated Transcranial Doppler Imaging | |
| US20110218421A1 (en) | Device and method for reducing the heart rate of a patient, and apparatus having the device | |
| US20230149744A1 (en) | Therapeutic inhibition and stimulation with transcranial ultrasound | |
| WO2025038540A2 (en) | Brain modulation systems and methods | |
| Yao et al. | Preventive and therapeutic effects of low-intensity ultrasound stimulation on migraine in rats | |
| Kim et al. | Magnetic Resonance-Guided High Intensity Focused Ultrasound for Treating Movement | |
| US20140364774A1 (en) | Ultrasound neuromodulation for clinical effects | |
| Fu et al. | Acoustic motor cortex stimulation enhances the descending analgesic pathway to alleviate chronic pain in mice | |
| Agyeman | Treatment Monitoring in Nervous System Disorders With Functional Ultrasound Imaging | |
| Sun et al. | Transcranial Ultrasound Stimulation | |
| Hesselink | Thesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |